Abstract

The abbreviated approval process for biosimilars leaves clinicians, payers, and other stakeholders with no product-specific clinical data to assess the safety and efficacy of the biosimilar product. Can real-world evidence fulfill the need for safety and efficacy data without eroding the cost advantages for biosimilars?